BioStrand (a subsidiary of IPA)

BioStrand is a subsidiary of ImmunoPrecise Antibodies (IPA), specializing in the intersection of biotech, life science, (bio)informatics, and AI. The company's unique strengths lie in its ability to analyze large datasets with exceptional accuracy, offering groundbreaking insights in therapeutic and diagnostic research. Their patented HYFT technology and LENSᵃⁱ ™ Integrated Intelligence Platform enable the application of these capabilities across various life science disciplines. Since its establishment in 2019, BioStrand has been dedicated to developing a cutting-edge end-to-end omics drug development platform, aiming to expedite discoveries and innovations in the industry. With a motto to "Let’s collaborate today," BioStrand is positioned as a compelling player in the integration of AI and antibody discovery and development. For more information, visit BioStrand.